- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02648880
Preoperative Exercise in Pancreatic Cancer
The Effects of a Preoperative Exercise Intervention During Neoadjuvant Therapy in Patients With Pancreatic Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study focuses on patients prescribed neoadjuvant (preoperative chemotherapy and radiation) prior to surgery for borderline resectable pancreatic adenocarcinoma. This allows for a known, preoperative window long enough to provide an effective exercise intervention. The exercise program will be administered for at least eight weeks, but has no cap on length, as neoadjuvent treatment periods can vary between participants and a cessation of the exercise program before the end of this period could result in an undesirable loss in physical fitness and function.
The study is a non-randomized, parallel group, intervention control trial, based on pilot studies in similar patient populations. All participants meeting the inclusion criteria and able to participate in the exercise program will be assigned to the exercise group. Participants meeting the inclusion criteria, but unable to commit to the exercise program for practical reasons (transportation, location, etc), will be assigned to the standard care group.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Colorado
-
Aurora, Colorado, United States, 80045
- University of Colorado Anschutz Health and Wellness Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Recent (< 4 week) first diagnosis of a borderline resectable pancreatic adenocarcinoma
- Prescription to receive neoadjuvant therapy and surgery,
- Age 21 to 80 years old,
- Physician clearance to participate in exercise program.
Exclusion Criteria:
- Any significant comorbid conditions that would interfere with or preclude participation in an exercise intervention, including orthopedic conditions such as advanced osteoarthritis, mobility-limiting amputations or chronic injuries, or mobility-limiting acute orthopedic injuries
- Advanced rheumatoid arthritis
- Widespread chronic pain conditions such as fibromyalgia
- Pulmonary conditions such as chronic obstructive pulmonary disease, emphysema, interstitial lung disease, use of supplementary oxygen
- Known cardiovascular disease or new cardiac event in last 6 months
- Diabetes
- Pregnancy
- Second cancer diagnosis at the time of enrollment
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Non-Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Exercise Group
Participants will complete an exercise program in addition to standard care.
Participants will start the exercise program within four weeks of their diagnosis and decision to undergo neoadjuvant treatment and continue until surgery.
Participants will be encouraged to complete three sessions per week for at least eight weeks during neoadjuvant therapy.
Exercise intensity, components, and time will be recorded for each exercise session.
Participants will schedule their sessions with the exercise specialists administering the program, typically taking place between 8AM and 4PM, Monday through Friday.
|
Individual exercise sessions in this program implement a "whole body" approach and consist of a 10-min cardiovascular warm-up and 50 minutes of cardiovascular endurance, resistance, and flexibility exercises.
Target intensity of exercise will be based on the American College of Sports Medicine recommendations for cancer survivors.
Prior to the start of exercise sessions, participants will be questioned on significant changes in symptoms or the presence of new symptoms (such as nausea or fever), which will used to modify the exercise session for that day to allow maximum symptom-limited participation.
The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition.
These services are provided by their oncology team.
|
|
Active Comparator: Standard Care
Participants in the Standard Care group will receive no exercise intervention, but will continue to receive standard follow-ups, treatments and services from their oncology team.
|
The services that participants receive as standard care include their medical care, symptom control, social worker support, and nutrition.
These services are provided by their oncology team.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in 400-meter Walk Time
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Assessment of physical fitness and function.
Participants are timed while walking 400 meters at a fast, but safe, pace.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Body Composition
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Assessment of physical fitness.
Dual-energy x-ray absorptiometry (DXA) will assess lean muscle mass and body fat.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Gait Speed
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Participant gait speed will be determined on a 10 meter course for both fast and self-selected paces.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Timed Up and Go
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Participants are timed as they rise from a chair, walk 3 meters, turn around, and return to the chair and sit.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Stair Climb Test
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Participants are timed as they ascend and descend one flight of stairs.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Single Limb Stance
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Participants are timed on how long they can balance on one leg.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in 30 Second Sit-to-Stand
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
The number of times a participant can rise from a chair in 30 seconds is counted.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Grip Strength
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
The maximum force the participant can produce separately with both hands, assessed by grip dynamometry, is measured.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Average Daily Step Count
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
The average step count for a minimum of 3 days over a 7 day period will be assessed with accelerometry.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Wellness
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
The Colorado Comprehensive Wellness Assessment, a survey, will be administered to assess eight domains of wellness.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Health-related Quality of Life
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
The Functional Assessment of Cancer Therapy - General Form (FACT-G), a survey, will be administered.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Perceived Fatigue
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Perceived fatigue will be assessed by the Revised Piper Fatigue Scale, a survey.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Anxiety
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Changes in state and trait anxiety will be assessed with the Spielberger State-Trait Anxiety Index.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Perceived Stress
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Changes in perceived stress will be assessed with the Perceived Stress Scale.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Resting Heart Rate Variability
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Heart rate variability will be assessed from electrocardiography (ECG) obtained during a 5 min rest period.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Heart Rate Variability Response to Physiologic Challenge
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Heart rate variability will be assessed from electrocardiography (ECG) obtained during a 5 min rest period, and changes in response to a physiologic challenge (orthostatic stress: chair rise).
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Heart Rate Variability Response to Mental Stressor
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Heart rate variability will be assessed from electrocardiography (ECG) obtained during a 5 min rest period, and changes in response to a mental challenge (Stroop Task).
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Heart Rate Variability Response to a Cancer-specific Mental Stressor
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Heart rate variability will be assessed from electrocardiography (ECG) obtained during a 5 min rest period, and changes in response to a cancer-specific mental challenge (Cancer-Specific Stroop Task).
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in C-reactive Protein
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Serum C-reactive protein will be assessed from blood draws.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Interleukin-6
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Serum interleukin-6 will be assessed from blood draws.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Soluble Tumor-necrosis Factor Receptor 1
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Soluble tumor-necrosis factor receptor 1 will be assessed from blood draws.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Change in Interleukin-10
Time Frame: Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
Serum interleukin-10 will be assessed from blood draws.
|
Baseline, Pre-operative (within the 2 weeks prior to surgery), 6 weeks postoperative
|
|
Determination of Hospital Length of Stay
Time Frame: 30 days after hospital discharge
|
At 30 days after discharge from the hospital, a medical record review will be conducted to determine the number of days participants were in the hospital after surgery.
|
30 days after hospital discharge
|
|
Determination of Hospital Readmission
Time Frame: 30 days after hospital discharge
|
At 30 days after discharge from the hospital, a medical record review will be conducted to determine whether participants were readmitted to the hospital for an unplanned surgical complication in the 30 days following hospital discharge.
|
30 days after hospital discharge
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 15-2266.cc
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Pancreatic Cancer
-
City of Hope Medical CenterRecruitingPancreatic Neoplasms | Pancreatic Cancer | Pancreatic Adenocarcinoma | Pancreatic Ductal Adenocarcinoma | Pancreatic Cancer Resectable | Pancreatic Carcinoma | Pancreatic Cancer Non-resectable | Pancreatic Cancer Stage III | Pancreatic Cancer Stage | Pancreatic Cancer Stage II | Pancreatic Cancer, Adult | Pancreatic... and other conditionsUnited States, Japan, South Korea
-
Sidney Kimmel Cancer Center at Thomas Jefferson...CelgeneWithdrawnPancreatic Ductal Adenocarcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
The First Affiliated Hospital with Nanjing Medical...Peking University Cancer Hospital & InstituteNot yet recruiting
-
Tianjin Medical University Cancer Institute and...Not yet recruiting
-
University of NebraskaNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic Cancer | Stage I Pancreatic Cancer | Resectable Pancreatic Carcinoma | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
University of UtahNovartis Pharmaceuticals; Huntsman Cancer InstituteTerminatedMetastatic Pancreatic Carcinoma | Unresectable Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IV Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage II Pancreatic CancerUnited States
-
Case Comprehensive Cancer CenterNational Cancer Institute (NCI)TerminatedPancreatic Adenocarcinoma | Resectable Pancreatic Cancer | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic Cancer | Poorly Differentiated Malignant Neoplasm | Undifferentiated Pancreatic CarcinomaUnited States
-
Virginia Commonwealth UniversityNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Recurrent Pancreatic Carcinoma | Stage III Pancreatic Cancer | Stage IIA Pancreatic Cancer | Stage IIB Pancreatic Cancer | Stage IA Pancreatic Cancer | Stage IB Pancreatic CancerUnited States
-
Memorial Sloan Kettering Cancer CenterActive, not recruitingPancreatic Cancer | Pancreatic Cancer Metastatic | Pancreatic Cancer Stage IV | Metastatic Pancreatic Carcinoma | Metastatic Pancreatic Adenocarcinoma | Pancreatic Carcinoma | Metastatic Pancreatic Cancer | Pancreatic Cancer Non-resectable | Metastatic Pancreatic Ductal Adenocarcinoma | Pancreatic Carcinoma... and other conditionsUnited States
-
UNC Lineberger Comprehensive Cancer CenterRecruitingPancreatic Neoplasms | Pancreas Adenocarcinoma | Pancreatic Cancer Resectable | Cancer of Pancreas | Pancreatic Cancer Non-resectable | Pancreatic Ductal Adenocarcinoma (PDAC) | Pancreatic Cancer, AdultUnited States
Clinical Trials on Exercise program
-
Azienda Sanitaria Locale CN1 CuneoRecruiting
-
Kafrelsheikh UniversityRecruitingLow Back Pain | Pilates Exercises | Nonspecific | Postnatal WomenEgypt
-
Hull University Teaching Hospitals NHS TrustTerminated
-
University of Vic - Central University of CataloniaCol·legi Fisioterapeutes de CatalunyaNot yet recruitingBreast Cancer | Physical Activity | Colorectal Cancer | Strength and Endurance | Lung Cancer (Non-Small Cell) | Neoadjuvant Chemotherapy ToleranceSpain
-
Marmara UniversityRecruitingTendinopathy | Shoulder PainTurkey
-
Munzur UniversityRecruiting
-
Akdeniz UniversityCompletedAnkylosing SpondylitisTurkey
-
University of AlexandriaCompleted
-
Chang Gung Memorial HospitalCompleted
-
Rosimeire Simprini PadulaUnknownMusculoskeletal Disorder of the NeckBrazil